Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant fragment corresponding to a region within amino acids 223 and 467 of Human MAP3K8|
|Purification||Antigen affinity chromatography|
|Storage buffer||0.1M tris glycine, pH 7, with 10% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100-1:1000|
|Western Blot (WB)||1:500-1:3000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-27765 targets MAP3K8 in IF, IHC (P), and WB applications and shows reactivity with Human samples.
The PA5-27765 immunogen is recombinant fragment corresponding to a region within amino acids 223 and 467 of Human MAP3K8.
This gene was identified by its oncogenic transforming activity in cells. The encoded protein is a member of the serine/threonine protein kinase family. This kinase can activate both the MAP kinase and JNK kinase pathways. This kinase was shown to activate IkappaB kinases, and thus induce the nuclear production of NF-kappaB. This kinase was also found to promote the production of TNF-alpha and IL-2 during T lymphocyte activation. Studies of a similar gene in rat suggested the direct involvement of this kinase in the proteolysis of NF-kappaB1,p105 (NFKB1). This gene may also utilize a downstream in-frame translation start codon, and thus produce an isoform containing a shorter N-terminus. The shorter isoform has been shown to display weaker transforming activity.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
augmented in rheumatoid arthritis 2; c-COT; cot (cancer Osaka thyroid) oncogene; EST; ESTF; Ewing sarcoma transformant; MEKK8; proto-oncogene c-Cot; proto-oncogene serine/threoine protein kinase; Tpl-2; TPL2; tumor progression locus 2
AURA2; c-COT; COT; EST; ESTF; MAP3K8; MEKK8; Tpl-2; TPL2